Department of Pharmaceutical Sciences, University of Connecticut, United States
Perspective
AdbryTM (tralokinumab-ldrm) Action towards Atopic Dermatitis
Author(s): Richard Dang*
Pharmaceutical Regulatory Affairs: Open Access received 533 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 